Davis's Drug Guide
durvalumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
dur-val-ue-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Imfinzi
Ther. Class.
Pharm. Class.
monoclonal antibodies
programmed death ligand 1 (PD-L1) inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Durvalumab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110575/7/durvalumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Durvalumab. Davis's Drug Guide. F.A. Davis Company; 2024. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110575/7/durvalumab. Accessed November 16, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Durvalumab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110575/7/durvalumab
Vallerand AHA, Sanoski CAC, Quiring CC. Durvalumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 November 16]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110575/7/durvalumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - durvalumab
ID - 110575
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110575/7/durvalumab
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
